Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Adult Congenital Heart Disease, Heart Failure

In brief

The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).

Key facts

Study ID
NCT06260059
Run by
Anita Saraf
People needed
40
Starts
2024-09-17
Expected to finish
2027-06-01
Last updated by the study team
2025-10-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.